Histogenics Corporation (Nasdaq: HSGX), to Ring The Nasdaq Stock Market Closing Bell
October 12 2016 - 10:00AM
What: Histogenics Corporation
(Nasdaq:HSGX), a regenerative medicine company focused on
developing and commercializing products in the musculoskeletal
space, will visit the Nasdaq MarketSite in Times Square, in
celebration of its recently closed $30 million financing.
In honor of the occasion, Adam Gridley, President and
Chief Executive Officer, will ring the Closing
Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Thursday, October 13, 2016 – 3:45 p.m. to
4:00 p.m. ET
Histogenics Media Contact:Jonathan
Lieber781.547.7909jlieber@histogenics.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company
developing and commercializing products in the musculoskeletal
segment of the marketplace. Histogenics’ regenerative medicine
platform combines expertise in cell processing, scaffolding, tissue
engineering, bioadhesives and growth factors to provide solutions
to treat musculoskeletal-related conditions. Histogenics’
first investigational product candidate, NeoCart®, is currently in
Phase 3 clinical development. NeoCart is an autologous cell
therapy designed to treat cartilage defects in the knee using the
patient’s own cells. Knee cartilage defects represent a
significant opportunity in the United States, with an
estimated 500,000 or more applicable procedures each year.
NeoCart is designed to exhibit characteristics of articular,
hyaline cartilage prior to and upon implantation into the knee and
therefore does not rely on the body to make new cartilage,
characteristics not exhibited in other current treatment
options. For more information, please
visit www.histogenics.com.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first electronic
stock market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to more than 3,700 listed companies with a market
value of approximately $9.3 trillion and nearly 18,000 corporate
clients. To learn more, visit: nasdaq.com/ambition or
business.nasdaq.com.
-NDAQA-
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Apr 2024 to May 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From May 2023 to May 2024